TY - JOUR
T1 - Pathologic complete response predicts recurrence-free survival more effectively by cancer subset
T2 - Results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657
AU - Esserman, Laura J.
AU - Berry, Donald A.
AU - DeMichele, Angela
AU - Carey, Lisa
AU - Davis, Sarah E.
AU - Buxton, Meredith
AU - Hudis, Cliff
AU - Gray, Joe W.
AU - Perou, Charles
AU - Yau, Christina
AU - Livasy, Chad
AU - Krontiras, Helen
AU - Montgomery, Leslie
AU - Tripathy, Debasish
AU - Lehman, Constance
AU - Liu, Minetta C.
AU - Olopade, Olufunmilayo I.
AU - Rugo, Hope S.
AU - Carpenter, John T.
AU - Dressler, Lynn
AU - Chhieng, David
AU - Singh, Baljit
AU - Mies, Carolyn
AU - Rabban, Joseph
AU - Chen, Yunn Yi
AU - Giri, Dilip
AU - Van't Veer, Laura
AU - Hylton, Nola
PY - 2012/9/10
Y1 - 2012/9/10
N2 - Purpose: Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter breast cancer study integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and their relationship and predictability based on tumor biomarkers. Patients and Methods: Eligible patients had tumors ≥ 3 cm and received neoadjuvant chemotherapy. We determined associations between pathologic complete response (pCR; defined as the absence of invasive cancer in breast and nodes) and RFS, overall and within receptor subsets. Results: In 221 evaluable patients (median tumor size, 6.0 cm; median age, 49 years; 91% classified as poor risk on the basis of the 70-gene prognosis profile), 41% were hormone receptor (HR) negative, and 31% were human epidermal growth factor receptor 2 (HER2) positive. For 190 patients treated without neoadjuvant trastuzumab, pCR was highest for HR-negative/HER2-positive patients (45%) and lowest for HR-positive/HER2- negative patients (9%). Achieving pCR predicted favorable RFS. For 172 patients treated without trastuzumab, the hazard ratio for RFS of pCR versus no pCR was 0.29 (95% CI, 0.07 to 0.82). pCR was more predictive of RFS by multivariate analysis when subtype was taken into account, and point estimates of hazard ratios within the HR-positive/HER2-negative (hazard ratio, 0.00; 95% CI, 0.00 to 0.93), HR-negative/HER2-negative (hazard ratio, 0.25; 95% CI, 0.04 to 0.97), and HER2-positive (hazard ratio, 0.14; 95% CI, 0.01 to 1.0) subtypes are lower. Ki67 further improved the prediction of pCR within subsets. Conclusion: In this biologically high-risk group, pCR differs by receptor subset. pCR is more highly predictive of RFS within every established receptor subset than overall, demonstrating that the extent of outcome advantage conferred by pCR is specific to tumor biology.
AB - Purpose: Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter breast cancer study integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and their relationship and predictability based on tumor biomarkers. Patients and Methods: Eligible patients had tumors ≥ 3 cm and received neoadjuvant chemotherapy. We determined associations between pathologic complete response (pCR; defined as the absence of invasive cancer in breast and nodes) and RFS, overall and within receptor subsets. Results: In 221 evaluable patients (median tumor size, 6.0 cm; median age, 49 years; 91% classified as poor risk on the basis of the 70-gene prognosis profile), 41% were hormone receptor (HR) negative, and 31% were human epidermal growth factor receptor 2 (HER2) positive. For 190 patients treated without neoadjuvant trastuzumab, pCR was highest for HR-negative/HER2-positive patients (45%) and lowest for HR-positive/HER2- negative patients (9%). Achieving pCR predicted favorable RFS. For 172 patients treated without trastuzumab, the hazard ratio for RFS of pCR versus no pCR was 0.29 (95% CI, 0.07 to 0.82). pCR was more predictive of RFS by multivariate analysis when subtype was taken into account, and point estimates of hazard ratios within the HR-positive/HER2-negative (hazard ratio, 0.00; 95% CI, 0.00 to 0.93), HR-negative/HER2-negative (hazard ratio, 0.25; 95% CI, 0.04 to 0.97), and HER2-positive (hazard ratio, 0.14; 95% CI, 0.01 to 1.0) subtypes are lower. Ki67 further improved the prediction of pCR within subsets. Conclusion: In this biologically high-risk group, pCR differs by receptor subset. pCR is more highly predictive of RFS within every established receptor subset than overall, demonstrating that the extent of outcome advantage conferred by pCR is specific to tumor biology.
UR - http://www.scopus.com/inward/record.url?scp=84856522259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856522259&partnerID=8YFLogxK
U2 - 10.1200/JCO.2011.39.2779
DO - 10.1200/JCO.2011.39.2779
M3 - Article
C2 - 22649152
AN - SCOPUS:84856522259
SN - 0732-183X
VL - 30
SP - 3242
EP - 3249
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 26
ER -